What is Quanterix's latest dividend and current dividend yield?

What guidance did Quanterix's management provide for the next earnings period?

What is Quanterix's gross profit margin?

What is the revenue and EPS growth rate for Quanterix year over year?

What were the key takeaways from Quanterix’s earnings call?

What factors drove the changes in Quanterix's revenue and profit?

What does Quanterix do and what are its main business segments?

What were the key takeaways from Quanterix's earnings call?

- **Revenue Growth**: Q4 2025 revenue of $43.9M (+25% YoY), driven by Simoa and Spatial platforms
- **Diagnostics Breakthrough**: CMS approves $897 reimbursement rate for LucentAD complete; FDA 510(k) submission filed
- **Cost Efficiency**: $74M of $85M cost synergies achieved, targeting H2 2026 cash flow breakeven
- **Innovation Pipeline**: 13 new assays launched in 2025, Simoa ONE platform in early access testing
- **Strategic Expansion**: 25+ diagnostics partnerships generating $9.6M in 2025, oncology pipeline expansion
- **Financial Health**: $122M cash on hand, no debt, targeting $100M by year-end

**【CEO Summary Section】**
- **New Leadership Focus**: Everett Cunningham emphasizes leveraging his 30+ years of healthcare experience to drive growth in diagnostics and tools businesses. Key priorities include accelerating Simoa and Spatial platforms, expanding diagnostics partnerships (e.g., Alzheimer's), and achieving 2026 breakeven profitability.
- **Market Positioning**: Quanterix is uniquely positioned with ultrasensitive proteomics platforms (Simoa) and spatial biology (Akoya) to address unmet needs in neurology, oncology, and immunology. 2025 revenue exceeded expectations, with diagnostics partnerships contributing $9.6M (vs. $6M prior year).
- **Integration Progress**: $74M of $85M cost synergy target achieved by Q1 2026, with focus shifting to profitable growth and remediating material weaknesses.

**【CFO Financial Commentary】**
- **Q4 2025 Results**: 
  - Total revenue: $43.9M (25% YoY growth, 7% sequential)
  - Simoa: $27M (-22% organic), Spatial: $17M (-23% organic)
  - Gross margin: 45.7% (GAAP), 50% (non-GAAP)
  - Operating expenses: $44.8M (GAAP), $37M (non-GAAP)
  - Cash: $122M (pre-acquisition), targeting $100M by year-end with no debt
- **2026 Guidance**: 
  - Revenue: $169-174M (2% YoY growth ex-terminated agreement)
  - Gross margin: 45-49% (GAAP), 49-53% (non-GAAP)
  - Cash flow breakeven in H2
- **Key Initiatives**: 
  - $897 CMS reimbursement rate for LucentAD complete
  - 510(k) submission for FDA approval
  - 13 new assays launched in 2025, 20+ planned for 2026
  - Simoa ONE platform in early access testing

**【Q&A Key Highlights】**
1. **Diagnostics Strategy**: 
   - Alzheimer's focus: LucentAD complete with CMS pricing, 6-9M FDA approval timeline
   - 25+ diagnostics partnerships generating $9.6M in 2025
   - Oncology pipeline expansion
2. **Product Pipeline**: 
   - Simoa ONE platform feedback from early access customers
   - 13 new assays launched in 2025, 20+ planned for 2026
3. **Financial Execution**: 
   - $74M cost synergies achieved, targeting $85M by Q1
   - Breakeven cash flow in H2 2026 despite $10M+ investments in diagnostics
4. **Market Dynamics**: 
   - Academic demand recovery (+22% Q4), pharma lab services down 21% YoY
   - Spatial business diversification (60% oncology vs. 10% pre-Akoya)
   - Accelerator lab services profitability focus

Quanterix Corporation (QTRX) Q4 2025 Earnings Call Transcript

- **Integration Success**: $67M of $85M synergies realized, ahead of plan, driving $120M 2025 cash target.
- **Growth Catalysts**: Simoa One early access program and LucentAD test expansion in Asia.
- **Revenue Resilience**: Q3 $40.2M despite Simoa decline, with Spatial stabilization signaling recovery.
- **2026 Outlook**: Cash flow breakeven, cross-selling opportunities, and diagnostics inflection.

**【CEO Summary Section】**
- Q3 2025 revenue of $40 million reflects strong execution post-Akoya integration, with $67 million of $85 million synergies realized.
- Simoa One early access program launched to gather feedback ahead of broader launch.
- Diagnostics revenue reached $2.4 million, driven by LucentAD test expansion in Asia.
- 2026 outlook includes cash flow breakeven and $120 million ending cash balance.

**【CFO Financial Commentary】**
- Total revenue $40.2 million (+12% YoY), with Simoa down 36% ($23M) and Spatial down 9% ($17.2M).
- Gross margin 42.8% (45.9% non-GAAP), benefiting from $67M synergies.
- Q4 guidance: $130-135M annual revenue, $120M cash by year-end.
- Operating expenses $54.5M, including $15M integration costs.

**【Q&A Key Highlights】**
- **Simoa Performance**: Sequential growth in instruments (16 placed vs. 13 YoY), but academic grant weakness impacts consumables.
- **Integration Progress**: Q4 focuses on lab consolidation, targeting full $85M synergies by Q1 2026.
- **Diagnostics Momentum**: LucentAD pricing approval expected, with $6M+ partner enablement revenue YTD.
- **Market Risks**: Government shutdown delays Q4 recovery, but pharma/Academic stabilization seen.
- **R&D Strategy**: Maintaining ~30% R&D spend to fuel Simoa One and diagnostics pipeline.

Quanterix Corporation (QTRX) Q3 2025 Earnings Call Transcript

- **Akoya Synergies Accelerating**: $85M annual savings by 2026 (75% implemented), expanding addressable market to $5B.
- **Revenue Challenges**: Q2 down 29% YoY due to pharma and academic headwinds, but stable consumables at $100M YoY.
- **Simoa One Expansion**: Launching by end-2025 to target 20,000 systems, tripling addressable market.
- **Diagnostic Growth**: Alzheimer's franchise doubles test volumes, triples revenue, on track for Medicare pricing.
- **Cash Flow Target**: Aim for breakeven in 2026 with $85M annual savings, supported by 49% QoQ cash usage improvement.

**【CEO Summary Section】**
- **Akoya Acquisition Integration**: Completed the Akoya acquisition, targeting $85M annual synergies by 2026 (75% implemented). Combined addressable market expanded to $5B, with 53% in neurology and 47% in immunology/oncology.
- **Revenue Performance**: Q2 revenue $24M (down 29% YoY) due to academic funding and pharma spending headwinds. Consumables stable at $100M YoY.
- **Product Expansion**: Launching Simoa One by end-2025, expanding addressable installed base to 20,000 systems globally. Alzheimer's diagnostics franchise doubled test volumes and tripled revenue.
- **R&D Investment**: 30% of revenue allocated to R&D, maintaining leadership in proteomics with Simoa and Spatial platforms.

**【CFO Financial Commentary】**
- **Q2 Financials**: Total revenue $24.5M (down 29% YoY). Academic sales -18%, pharma -38%. Gross margin 46.2% (GAAP), 41.8% (non-GAAP) due to lower demand and inventory reserves.
- **Cost Management**: Operating expenses $48.4M (up $15.2M YoY) due to acquisition costs and $6.4M goodwill impairment. Adjusted EBITDA loss $13.7M.
- **Cash Position**: $263.8M cash, with adjusted cash usage improving 49% QoQ. 2025 guidance: $130-135M revenue, 49-53% GAAP gross margin, $85M annual savings by 2026.

**【Q&A Highlights】**
- **Accelerator Growth**: 40% YoY growth but smaller project sizes; expects recovery with improved budgets.
- **Academic Resilience**: Consumables stable at $100M YoY, despite macro challenges.
- **Cost Synergies**: Achieved through commercial, operations, and lab integration; $85M annual savings target on track.
- **Future Growth**: Investing in instruments and diagnostics, with Simoa One and Spatial Biology as key drivers.

Quanterix (QTRX)-7 Aug 25-2025 Q2 Earnings call transcript

- **Q1 2025 Results**: Revenue $30.3M (-5% YoY), driven by 6% consumables growth.\n- **2026 Cash Flow Target**: $100M+ cash balance with positive cash flow.\n- **Simoa ONE Innovation**: 10x sensitivity on flow cytometers, 2026 launch.\n- **Akoya Synergies**: 37% top line contribution, $55M cost savings.\n- **Alzheimer's Expansion**: ARUP partnership, LucentAD pricing Q3 2025.\n

**【CEO Opening Remarks】**
- Q1 2025 revenue of $30.3M (-5% YoY) driven by strong consumables (+6%) despite instrument sales pressure.\n- Announced revised 2025 guidance ($120-130M) due to macro funding headwinds, targeting 2026 cash flow breakeven.\n- Highlighted key initiatives: Simoa ONE platform launch (Q4 2025), Akoya merger (now 84% Quanterix ownership), and $30M cost reduction plan.\n- Expanded Alzheimer's diagnostics with ARUP partnership and LucentAD Complete test pricing announcement for Q3 2025.\n- Introduced 'democratization' strategy for 2026, enabling access to Simoa ONE assays on existing flow cytometers without capital investment.\n
**【CFO Financial Update】**
- GAAP gross margin 54.1%, non-GAAP 49.7% (down 150bps YoY due to inventory reserves).\n- Adjusted EBITDA loss $11.3M vs. $8.1M prior year, with $9M cash burn (50% improvement YoY).\n- Q1 2025 cash balance $269.5M, down $22.2M YoY due to Akoya deal and EMISSION payments.\n- 2025 cash usage forecast $35-45M from operations + $20M for Akoya-related costs.\n- Post-merger 2026 targets: >$100M cash balance, $55M annualized cost savings, and positive cash flow.\n
**【Q&A Key Themes】**
1. **Accelerator Lab Softness**:\n- Q1 revenue down 36% vs. prior year, driven by $1.5M Lilly project loss.\n- Pipeline visibility limited; pharma customers delaying projects.\n- 50% recurring revenue mix provides stability, but large project delays weigh on growth.\n
2. **Simoa ONE Platform**:\n- 10x sensitivity improvement vs. HD-X, 10-plex capability, and code-matched barcoding.\n- 2026 'democratization' plan enables use on 20,000+ existing flow cytometers.\n- Expected synergies with Akoya in oncology and immunology applications.\n
3. **Alzheimer's Diagnostics**:\n- ARUP partnership brings pTau217 test to 20M+ patients.\n- LucentAD Complete test to launch Q3 2025 with triple-digit pricing.\n- 2025 revenue $6M+ from collaborations, scaling to $100M+ opportunity.\n
4. **Akoya Merger Synergies**:\n- Akoya contributes 37% to combined top line, 40% to gross profit.\n- $55M annualized cost savings by 2026 (up from $40M prior guidance).\n- Expanded addressable market from $1B to $5B.\n

Quanterix (QTRX)-12 May 25-2025 Q1 Earnings call transcript

- **Q4 2024 Strong Execution**: $35.2M revenue (+11% YoY), 57.7% non-GAAP margin, 22% Accelerator lab growth.
- **Akoya Merger Strategic Fit**: $40M synergies, 2026 free cash flow breakeven, $1B+ revenue target.
- **Simoa ONE Platform Expansion**: Immunology assays launching Q4 2025 to address $5B+ adjacencies.
- **Diagnostics Momentum**: 12 new partners, $6M 2024 revenue, FDA submission planned for Alzheimer's test.
- **2025 Guidance Caution**: Q1 down 10-15% YoY due to academic funding delays, targeting 2026 cash flow breakeven.

**【CEO Opening Remarks】**
- Q4 2024 revenue of $35.2M (+11% YoY), driven by 22% growth in Accelerator lab services and $2.7M in partner-enabled diagnostics revenue.
- Non-GAAP gross margin improved 300bps to 57.7%, citing higher-margin consumables and operational efficiency.
- Strategic focus on three pillars: 
  1. Menu expansion (13 new neurology assays in 2024, Simoa ONE platform launch Q4 2025)
  2. Adjacent market expansion (Akoya Biosciences merger to combine blood/tissue biomarker detection)
  3. Diagnostic infrastructure (12 new partners for Alzheimer's testing, FDA submission planned)
- Akoya acquisition: $40M cost synergies by 2026, targeting $1B revenue and 15% EBIT margin in five years post-close.

**【CFO Financial Details】**
- Full year 2024 revenue $137.4M (+12% YoY), with 54% pharma/46% academia split.
- GAAP gross profit $83.1M (60.4% margin), non-GAAP $75M (54.6% margin).
- 2025 guidance: $140-146M revenue (-10-15% Q1 YoY due to academic funding delays)
  - GAAP gross margin 59-63%, non-GAAP 53-57%
  - Cash usage $35-45M (includes $30M in diagnostics/Simoa ONE investments)
- Simoa ONE launch expected to drive 2026+ growth, targeting RUO cash flow breakeven by 2027-28.

**【Key Q&A Highlights】**
1. **Academic Market Concerns**
- Q1 2025 down 10-15% YoY due to NIH funding paralysis, but pharma Accelerator pipeline remains strong.
- 50% of Advantage PLUS consumable transition complete, on track for mid-2025 completion.

2. **Akoya Merger Valuation**
- $40M cost synergies (100% realized by 2026), including $10M/quarter in SG&A savings.
- Combined TAM expands from $11B to $25B, with 2026 free cash flow breakeven vs. 2028 standalone.

3. **Simoa ONE Platform**
- Launching Q4 2025 with immunology assays, targeting non-neurology markets.
- Will complement existing Simoa HD platform rather than replace it.

4. **Diagnostics Growth**
- 10 new hospitals/labs in validation phase for LucentAD Complete test.
- 2024 partner-enabled revenue $6M, expected to grow with new partnerships.


Actual										-0.41	-0.43	0.0732	-0.3098	-0.2937	-0.3277	-0.4291	-0.5457	-0.49	-0.67	-0.95	-0.5	-0.16	-0.16	-0.21	-0.33	-0.26	-0.25	-0.2186	-0.3	-0.53	-0.77	-0.73	-0.49
Forecast										-0.4009	-0.4762	-0.418	-0.3292	-0.3316	-0.3319	-0.3559	-0.6578	-0.6065	-0.5703	-0.4389	-0.4675	-0.382	-0.3775	-0.3679	-0.314	-0.309	-0.266	-0.2443	-0.2547	-0.435	-0.4225	-0.4575	-0.4489
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2.27%	+9.70%	+117.51%	+5.89%	+11.43%	+1.27%	-20.57%	+17.04%	+19.21%	-17.48%	-116.45%	-6.95%	+58.12%	+57.62%	+42.92%	-5.10%	+15.86%	+6.02%	+10.52%	-17.79%	-21.84%	-82.25%	-59.56%	-9.16%

QTRX

QTRX fundamentals

QTRX Q4 2025 Earnings

Earnings Call

You can ask Aime

QTRX

QTRX fundamentals

QTRX Q4 2025 Earnings

Earnings Call

QTRX Earnings Call Summary for Q4/20254:30 PM on Mar 2, 2026

QTRX Earnings Call Summary for Q3/20254:30 PM on Nov 10, 2025

QTRX Earnings Call Summary for Q2/20254:30 PM on Aug 7, 2025

QTRX Earnings Call Summary for Q1/20254:30 PM on May 12, 2025

QTRX Earnings Call Summary for Q4/20244:30 PM on Mar 17, 2025

You can ask Aime